首页> 美国卫生研究院文献>BMJ Open Diabetes Research Care >Improved diabetes medication convenience and satisfaction in persons with type 2 diabetes after switching to insulin glargine 300 U/mL: results of the observational OPTIN-D study

【2h】

Improved diabetes medication convenience and satisfaction in persons with type 2 diabetes after switching to insulin glargine 300 U/mL: results of the observational OPTIN-D study

机译：转换为甘精胰岛素300 U / mL后2型糖尿病患者的糖尿病用药便利性和满意度得到改善：观察性OPTIN-D研究的结果

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

ObjectiveInsulin glargine 300 (Gla-300) provides less hypoglycemia risk and more flexibility in injection time. The extent to which these effects translate into improved patient-reported outcomes (PROs) is unknown, and is the subject of this observational study.

机译：目的甘精胰岛素300（Gla-300）可降低低血糖风险，并在注射时间上具有更大的灵活性。这些作用转化为改善的患者报告结局（PROs）的程度尚不清楚，并且是本观察研究的主题。

著录项

期刊名称 BMJ Open Diabetes Research Care
作者
Thomas H Wieringa; Maartje de Wit; Jos WR Twisk; Frank J Snoek;
展开▼
作者单位

展开▼
年(卷),期 2018(6),1
年度 2018
页码 e000548
总页数 8
原文格式 PDF
正文语种
中图分类心血管疾病;
关键词
well-being patient-reported outcomes insulin treatment in type 2 diabetes treatment satisfaction;

机译：健康;患者报告的结局;2型糖尿病的胰岛素治疗;治疗满意度;

相似文献

外文文献
中文文献
专利

1. A 1‐year, prospective, observational study of Japanese outpatients with type 1 and type 2 diabetes switching from insulin glargine or detemir to insulin degludec in basal–bolus insulin therapy (Kumamoto Insulin Degludec Observational study) [J] . Shimoda Seiya, Sato Miki, Sekigami Taiji, Journal of diabetes investigation. . 2016,第5期

机译：一项为期1年的前瞻性观察性研究，对日本的1型和2型糖尿病门诊患者在基础推注胰岛素治疗中从甘精胰岛素或地特米尔胰岛素转为地格列酮胰岛素（熊本Insulin Degludec观察研究）
2. Treatment Dosing Patterns and Clinical Outcomes for Patients with Type 2 Diabetes Starting or Switching to Treatment with Insulin Glargine (300 Units per Milliliter) in a Real-World Setting: A Retrospective Observational Study [J] . Shaloo Gupta, Hongwei Wang, Neil Skolnik, Advances in therapy. . 2018,第1期

机译：治疗剂量2型糖尿病患者的治疗剂量和临床结果，从实际世界环境中与胰岛素狼蛛（每毫升300个单位）进行治疗：回顾性观察研究
3. Glycaemic control and hypoglycaemia in people with type 2 diabetes switching from twice‐daily basal insulin to once‐daily insulin glargine 300 U/mL or insulin glargine 100 U/mL ( EDITION EDITION 1 and EDITION EDITION 2 subgroup analysis) [J] . Roussel Ronan, dEmden Michael C., Fisher Miles, Diabetes, obesity & metabolism . 2018,第2期

机译：血糖控制和2型糖尿病的低血糖从两次的基础胰岛素切换到曾经每日胰岛素的胰岛素300 u / ml或胰岛素龟头100 U / ml（版本版本1和Edition Edition 2亚组分析）
4. Switching to insulin glargine 300 U/mL from other basal insulin analogues provides less 24-hour glucose variability in hospitalized patients with type 1 diabetes [C] . V.V. Klimontov, E.A. Koroleva, O.N. Fazullina International Multiconference Bioinformatics of Genome Regulation and StructureSystems Biology . 2018

机译：从其他基础胰岛素类似物转换为甘精胰岛素300 U / mL可使住院的1型糖尿病患者的24小时葡萄糖变异性降低
5. Physiology and pharmacology of diabetes therapies in the cat: Insulin detemir, insulin glargine, exenatide and the incretin effect. [D] . Gilor, Chen. 2010

机译：猫的糖尿病疗法的生理和药理作用：地特胰岛素，甘精胰岛素，艾塞那肽和肠降血糖素作用。
6. A 1‐year prospective observational study of Japanese outpatients with type 1 and type 2 diabetes switching from insulin glargine or detemir to insulin degludec in basal–bolus insulin therapy (Kumamoto Insulin Degludec Observational study) [O] . Seiya Shimoda, Miki Sato, Taiji Sekigami, 2016

机译：一项为期1年的前瞻性观察性研究针对日本的1型和2型糖尿病患者在基础推注胰岛素治疗中从甘精胰岛素或地特米尔胰岛素转为地格列酮胰岛素（熊本Insulin Degludec观察性研究）
7. Treatment Dosing Patterns and Clinical Outcomes for Patients with Type 2 Diabetes Starting or Switching to Treatment with Insulin Glargine (300 Units per Milliliter) in a Real-World Setting: A Retrospective Observational Study [O] . Shaloo Gupta, Hongwei Wang, Neil Skolnik, 2018

机译：用于2型糖尿病患者的治疗剂量和临床结果开始或切换与胰岛素狼（MilliLiter）在真实世界的环境中的治疗：回顾性观察研究

Improved diabetes medication convenience and satisfaction in persons with type 2 diabetes after switching to insulin glargine 300 U/mL: results of the observational OPTIN-D study

摘要

著录项

相似文献

相关主题

期刊订阅